B-OM hasn't been granted rolling review yet. It's
Post# of 72440
Leo said the trial has an adaptive design, which means it could turn into a P3 during P2. But this information hasn't made public yet.
http://investorshangout.com/post/view?id=2995833
Quote:
correct me if I'm wrong but isn't the B-OM trial on a rolling review also.